Genetic test that predicts cognitive decline available soon

LabPulse.com staff writers
Jun 22, 2021
2021 06 23 21 28 5659 Woman Dementia Alzheimer 400

A genetic test that uses a saliva or blood sample to predict a person's risk of cognitive decline due to Alzheimer's disease is expected to be available to doctors in the coming months.

The test, genoScore, is a collaboration between Infinity BiologiX and Cytox and can be used to assess patients before symptoms arise and prior to invasive cerebrospinal fluid testing. Additionally, the test gives patients the convenience of collecting samples at home.

Latest in Molecular Diagnostics
Crispr Cas9 Gene Editing Social
KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy
November 29, 2023
Dna Sequence Social
Nanopore sequencing slashes tumor analysis times and costs
November 28, 2023
Liver Anatomy Social
Bit.bio unveils cell therapy candidate for liver conditions
November 22, 2023
Sickle Cell Anemia2 Social
U.K. regulators approve "world-first" sickle-cell gene therapy
November 20, 2023
Related Stories
2020 04 16 18 56 8041 Virus Coronavirus Sars Co V 2 400
COVID-19
Infinity BiologiX test can detect omicron variant of COVID-19
2020 03 31 23 03 5810 Brain Dementia Leaves 400
Alzheimer's
Quanterix announces kit for Alzheimer's disease detection
2019 07 15 19 08 6013 Amyloid Plaque Alzheimer 400
Alzheimer's
AAIC update: Where blood-based dementia tests stand in 2019
2017 09 14 23 05 1167 Cancer Cell 400
Sequencing
Adela launches with $60M investment
More in Molecular Diagnostics
KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy
Biotech firm KSQ Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a phase I and II trial of KSQ-001EX, KSQ’s CRISPR-Cas9 engineered tumor-infiltrating lymphocyte program.
November 29, 2023
Crispr Cas9 Gene Editing Social
Nanopore sequencing slashes tumor analysis times and costs
Nanopore sequencing makes the analysis of copy number variations (CNVs) faster, cheaper, and simpler, according to a preprint paper from researchers at Dartmouth-Hitchcock Medical Center.
November 28, 2023
Dna Sequence Social
Bit.bio unveils cell therapy candidate for liver conditions
Synthetic biology company bit.bio has unveiled a lead cell therapy candidate as a treatment for life-threatening liver conditions, and it has set out its broader cell therapy pipeline.
November 22, 2023
Liver Anatomy Social
U.K. regulators approve "world-first" sickle-cell gene therapy
U.K. medical regulators have approved a “world-first” gene therapy that aims to cure two blood disorders: sickle cell disease and transfusion-dependent β-thalassemia. They are the first regulatory body to approve the treatment.
November 20, 2023
Sickle Cell Anemia2 Social
Verici DX, Thermo Fisher Scientific sign licensing agreement on pre-transplant prognostic test
Transplant diagnostic firm Verici DX and Thermo Fisher Scientific have signed an exclusive global licensing and commercialization agreement to develop a pre-transplant prognostic test for early kidney rejection risk assessment.
November 17, 2023
Kidneys Closeup Social
Zymo Research, Ad Astra Diagnostics receive FDA 510(k) clearances
Molecular diagnostics firm Zymo Research and rapid diagnostics developer Ad Astra Diagnostics have both received 510(k) clearances from the U.S. Food and Drug Administration.
November 16, 2023
Fda Button Social
AnchorDx, DiaCarta to collaborate on cancer diagnostics
Biotech company AnchorDx has entered into a long-term partnership with molecular diagnostics firm DiaCarta to develop and commercialize cancer diagnostic products for the global market.
November 14, 2023
Hands Shaking Deal Social
Illumina launches pricing program for pathogen sequencing tools in LMICs
Illumina has launched its Global Health Access Initiative program to provide pathogen sequencing tools at lower prices in low- and middle-income countries (LMICs).
November 13, 2023
Infectious Diseases Research Social
Pan-cancer study reveals epigenomic drivers for cancer development, progression
A team of researchers have identified epigenomic drivers associated with cancer development and progression, constructing a pan-cancer epigenetic and transcriptomic atlas from the data.
November 3, 2023
Cancer Cell Microenvironment Social
U.K. trial approved for Hunter syndrome gene therapy
U.K. regulators have approved the “first ever” trial of a revolutionary gene therapy for young children diagnosed with Hunter syndrome, a rare lysosomal storage disorder.
November 9, 2023
Gene Therapy Dna Scientist Social
Velsera, Solaris Health partner to expand genetic testing access to urology practices
Healthcare technology company Velsera and urological services platform Solaris Health are collaborating to expand access to genetic testing to cancer patients and their physicians at urology practices affiliated with Solaris.
November 8, 2023
Lab Test Tube Dna Blood Social
Genomics England, Oxford Nanopore to collaborate on sequencing rare diseases
Genomics England and Oxford Nanopore Technologies have announced a strategic research partnership to resolve undiagnosed rare disease cases.
November 7, 2023
Cell Gene Therapy Dna Social
Page 1 of 190
Next Page